Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6537-6542

  Sheu, Bor Ching ^a   Lien, Huang Chun ^a   Ho, Hong Nerng ^a   Lin, Ho Hsiung ^a   Chow, Song Nan ^a   Huang, Su Cheng ^a   Hsu, Su Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; GELATINOL; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; RECEPTOR UPREGULATION; RNA TRANSLATION; SQUAMOUS EPITHELIUM; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; NEOPLASM RECURRENCE, LOCAL; PRECANCEROUS CONDITIONS; STROMAL CELLS; TISSUE INHIBITOR OF METALLOPROTEINASES; UTERINE CERVICAL NEOPLASMS;

EID: 0141953315     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Liotta, L. A., and Kohn, E. C. The microenvironment of the tumor-host interface. Nature (Lond.) 411: 375-379, 2001.
2. Egeblad, M., and Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. (Loud.), 2: 163-176, 2002.
3. Garzetti, G. G., Ciavattini, A., Lucarini, G., Goteri, G., Nictolis, M. D., and Biagini, G. Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol. Oncol., 61: 97-203, 1999.
4. Nuovo, G. J., MacConnell, P. B., Simsir, A., Valea, F., and French, D. L. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res., 55: 267-275, 1995.
5. Gilles, C., Polette, M., Piette, J., Munaut, C., Thompson, E. W., Birembaut, P., and Foidart, J-M. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int. J. Cancer, 65: 209-213, 1996.
6. Kurman, R. J. Blaustein's Pathology of the Female Genital Tract, pp. 325-381. New York: Springer-Verlag, 2002.
7. Birkedal-Hansen, H., and Taylor, R. E. Detergent-activation of latent collagenase and resolution of its component molecules. Biochem. Biophys. Res. Commun., 107: 1173-1178, 1982.
8. Sawaya, R., and Highsmith, R. Plasminogen activator activity and molecular weight patients in human brain tumors. J. Neurosurg., 68: 73-79, 1998.
9. Davies, B., Miles, D. W., Happerfield, L. C., Naylor, M. S., Bobrow, L. G., Rubens, R. D., and Balkwill, F. R. Activity of type IV collagenases in benign and malignant breast disease. Br. J. Cancer, 67: 1126-1131, 1993.
10. Kumar, A., Collins, H. M., Scholefield, J. H., and Watson, S. A. Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer. Br. J. Cancer, 82: 960-965, 2000.
11. Tamakoshi, K., Kikkawa, F., Nawa, A., Ishikawa, H., Mizuno, K., Tamakoshi, A., Yamagata, S., Suganuma, N., and Tomoda, Y. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer (Phila.), 76: 2565-2571, 1995.
12. Johnsen, M., Lund, L. R., Romer, J., Almholt, K., and Danø, K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr. Opin. Cell. Biol., 10: 667-671, 1998.
13. Johansson, N., Vaalamo, M., Grénman, S., Hietanen, S., Klemi, P., Saarialho-Kere, U., and Kähäri, V-M. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am. J. Pathol., 154: 469-480, 1999.
14. Nakamura, H., Ueno, H., Yamashita, K., Shimada, T., Yamamoto, E., Noguchi, M., Fujimoto, N., Sato, H., Seiki, M., and Okada, Y. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res., 59: 467-473, 1999.
15. Ueno, H., Yamashita, K., Azumano, I., Inoue, M., and Okada, Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int. J. Cancer (Pred. Oncol.), 84: 470-477, 1999.
16. Yamashita, K., Azumano, I., Mai, M., and Okada, Y. Expression and tissue localization of matrix metalloproteinase-7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int. J. Cancer (Pred. Oncol.), 79: 187-194, 1998.
17. Davidson, B., Goldberg, I., Kopolovic, J., Lerner-Geva, L., Gotlieb, W. H., Weis, B., Ben-Baruch, G., and Reich, R. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix - clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol. Oncol., 72: 380-386, 1999.
18. Davidson, B., Goldberg, I., Kopolovic, J., Lerner-Geva, L., Gotlieb, W. H., Ben-Baruch, G., and Reich, R. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol. Oncol., 73: 372-382, 1999.
19. Parsons, S. L., Watson, S. A., Collins, H. M., Griffin, N. R., Clarke, P. A., and Steele, R. J. C. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br. J. Cancer, 78: 1495-1502, 1998.
20. Kawamata, H., Uchida, D., Hamano, H., Kimura-Yanagawa, T., Nakashiro, K., Hino, S., Omotehara, F., Yoshida, H., and Sato, M. Active MMP-2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int. J. Oncol., 13: 699-704, 1998.
21. Nomura, H., Fujimoto, N., Seiki, M., and Okada, Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int. J. Cancer (Pred. Oncol.), 69: 9-16, 1996.
22. Sheu, B-C., Lin, R-H., Ho, H-N., and Huang, S-C. Down-regulation of CD25 expression on activated tumour-infiltrating lymphocytes derived from human cervical carcinoma. Hum. Immunol., 56: 39-47, 1997.
23. Sheu, B-C., Hsu, S-M., Ho, H-N., Lien, H-C., Huang, S-C., and Lin, R-H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res., 61: 237-242, 2001.
24. Ito, A., Mukaiyama, A., Itoh, Y., Nagase, H., Thogersen, I. B., Enghild, J. J., Sasaguri, Y., and Mori, Y. Degradation of interleukin-1β by matrix metalloproteinases. J. Biol. Chem., 271: 14657-14660, 1996.
25. Moss, M. L., Jin, S-L. C., Milla, M. E., Burkhart, W., Carter, H. L., Chen, W-J., Clay, W. C., Didsbury, J. R., Hassler, D., Hoffman, C. R., Kost, T. A., Lambert, M. H., Leesnitzer, M. A., McCauley, P., McGeehan, G., Mitchell, J., Moyer, M., Pahel, G., Rocque, W., Overton, L. K., Schoenen, F., Seaton, T., Su, J-L., Warner, J., Willard, D., and Becherer, J. D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Nature (Lond.), 385: 733-736, 1997.
26. Nagase, H. Activation mechanisms of matrix metalloproteinases. Biol. Chem., 378: 151-160, 1997.
27. Urbanski, S. J., Edwards, D. R., Maitland, A., Leoo, K. J., Watson, A., and Kossakowska, A. E. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br. J. Cancer, 66: 188-1194, 1992.
28. Murray, G. I., Duncan, M. E., O'Neil, P., Melvin, W. T., and Fothergill, J. E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med., 2: 461-462, 1996.
29. Johansson, N., Airola, K., Grénman, R., Kariniemi, A-L., Saarialho-Kere, U., and Kähäri, V-M. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am. J. Pathol., 151: 499-508, 1997.
30. Määttä, M., Soini, Y., Liakka, A., and Autio-Harmainen, H. Different expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type-1 MMP in hepatocellular and pancreatic adenocarcinoma: implication for tumor progression and clinical prognosis. Clin. Cancer Res., 6: 2726-2734, 2000.
31. Schmalfeldt, B., Prechtel, D., Härting, K., Späthe, K., Rutke, S., Konik, E., Fridman, R., Berger, U., Schmitt, M., Kuhn, W., and Lengyel, E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res., 7: 2396-2404, 2001.
32. Kallakury, B. V. S., Karikehalli, S., Haholu, A., Sheehan, C. E., Azumi, N., and Ross, J. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor progrestic variables in renal cell carcinoma. Clin. Cancer Res., 7: 3113-3119, 2001.
33. Nuovo, G. J. In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell clines. Int. J. Cancer, 71: 1056-1060, 1997.
34. Lu, J., Chua, H-H. Chen, S-Y., Chen, J-Y., and Tsai, C-H. Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res., 63: 256-262, 2003.
35. Coussens, L. M., Fingleton, B., and Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash. DC), 295: 2387-2392, 2002.